← All trials
NCT06387069
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 26, 2024
- Primary completion
- Jun 3, 2027
- Completion date
- Jun 29, 2028
- First posted
- Apr 26, 2024
- Last posted
- May 30, 2024
- Enrollment
- 316
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of WashingtonLead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.